This overview examines multidrug-resistant Klebsiella pneumoniae infections, highlighting urgent public health challenges.
Klebsiella pneumoniae - gram-negative, non-motile bacteria which is fit in to the family of Enterobacteriaceae; found in the human digestive tract. This bacterium is significant adaptable pathogen and responsible for a wide range of infections such as pneumonia, UTI, septicaemia and wound infections, predominantly in immune-compromised persons and hospitalized patients. This organism is characterized by noticeable polysaccharide encoded capsule that develops virulence by protecting against phagocytosis and host immune responses. Right now, Klebsiella has gained attention due to the emergence of multidrug-resistant (MDR) and highly virulent strains, specifically producing broad-spectrum β-lactamases (ESBLs) and carbapenems. This resistance systems severely limit therapeutic options and main challenge to worldwide public health management. Transmission normally happens via unclean hands, medical instruments, and hospital circumstances. First diagnosis, suitable antimicrobial treatment, and exact adherence to hygiene performs are critical in managing infections caused by Klebsiella. Current research focuses on new therapy strategies, with different antibiotics, bacteriophage therapy procedure, and vaccines, to fight increasingly resistant pathogen.
No takes yet. Share an insight, caveat, or question.
Arunima Ghosh1, Kingshuk Mandal2, Sanchaita Bera3, Souparno Paria5, Moulima Maity4* (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: